Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Bausch Health Companies Inc.NYSE: BHC
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 5.7% from a year ago
Cash & equivalents stood at $1.83B at the end of Q2 FY2026, up 5.7% from a year earlier and up 40.5% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.
Context
- Cash & equivalents amounted to 7.4% of total assets at the end of Q2 FY2026, up 1.0 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.32B USD
- Year-over-year change
- +12.0%
- 4-year CAGR
- +22.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.32B | +12.0% |
| FY2024 | 2024-12-31 | 1.18B | +24.7% |
| FY2023 | 2023-12-31 | 947M | +67.9% |
| FY2022 | 2022-12-31 | 564M | -3.1% |
| FY2021 | 2021-12-31 | 582M | — |
Cash & Equivalents vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's Jun 2026 cash & equivalents of $1.83B is the highest of the 11 companies compared; the peer median is $204.91M.
- Its year-over-year change of +5.7% is the 6th highest of 11, against a peer median of +9.1%.
- Cash & equivalents amounts to 7.4% of total assets for BHC, versus a peer median of 7.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.83B | +5.7% | +32.9% | 7.4% | |
| Mar 2026 | $755.86M | +30.2% | +33.5% | 65.9% | |
| Jun 2026 | $399.7M | -12.0% | -4.0% | 5.3% | |
| Mar 2026 | $311.18M | +107.7% | +80.9% | 21.9% | |
| Jun 2026 | $223.38M | -23.7% | -4.8% | 9.4% | |
| Jun 2026 | $219.83M | -22.1% | +8.2% | 15.9% | |
| Mar 2026 | $190M | -52.3% | -3.7% | 3.6% | |
| Jun 2026 | $138.27M | +35.8% | +25.4% | 20.7% | |
CONConcentra Group Holdings Parent, Inc. | Sep 2026 | $85.82M | +71.8% | +28.5% | 2.8% |
| Dec 2025 | $71.33M | -53.7% | -38.9% | 4.1% | |
| Mar 2026 | $63.83M | +65.6% | +37.4% | 4.5% | |
| Peer median (excluding BHC) | $204.91M | +9.1% | +16.8% | 7.3% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 582M | 564M | 947M | 1.18B | 1.32B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.78B | 1.79B | 2B | 2.14B | 2.35B |
| Inventory | 993M | 1.09B | 1.54B | 1.6B | 1.63B |
| Other Current Assets | 1.54B | 39M | 1.11B | 858M | 850.45M |
| Total Current Assets | 5.61B | 4.25B | 5.6B | 5.77B | 6.15B |
| Property, Plant & Equipment (Net) | 1.6B | 1.6B | 1.71B | 1.78B | 2.07B |
| Goodwill | 12.46B | 11.55B | 11.18B | 11.09B | 11.25B |
| Intangible Assets | 6.95B | 5.8B | 6.46B | 5.55B | 4.63B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 2.25B | 2.17B | 2.1B | 1.97B | 1.84B |
| Other Non-current Assets | 340M | 326M | 307M | 363M | 377.31M |
| Total Non-current Assets | 23.6B | 21.44B | 21.75B | 20.75B | 20.17B |
| Total Assets | 29.2B | 25.69B | 27.35B | 26.52B | 26.32B |
| Account Payables | 407M | 521M | 719M | 656M | 598.91M |
| Short-term Debt | 0 | 432M | 450M | 2.67B | 296.46M |
| Tax Payables | 98M | 30M | 47M | 63M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.98B | 1.34B | 1.4B | 1.33B | 2.85B |
| Total Current Liabilities | 5.2B | 3.94B | 4.3B | 6.75B | 4.17B |
| Long-term Debt | 22.65B | 20.33B | 21.94B | 18.94B | 20.72B |
| Deferred Tax Liabilities | 529M | 202M | 163M | 128M | 146.73M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 855M | 949M | 1.03B | 857.49M | 711.7M |
| Total Non-current Liabilities | 24.04B | 21.49B | 23.13B | 20.09B | 21.77B |
| Total Liabilities | 29.24B | 25.43B | 27.43B | 26.85B | 25.94B |
| Common Stock | 10.32B | 10.39B | 10.42B | 10.49B | 10.5B |
| Retained Earnings | (8.96B) | (9.19B) | (9.78B) | (9.82B) | (9.65B) |
| Accumulated OCI | (1.92B) | (2.06B) | (1.88B) | (2.18B) | (1.76B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 72M | 952M | 940M | 957M | 929.31M |
| Total Equity | (34M) | 260M | (82M) | (322M) | 376.31M |
| Total Debt | 22.65B | 20.77B | 22.39B | 21.83B | 21.21B |
| Net Debt | 22.07B | 20.2B | 21.44B | 20.65B | 19.88B |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.